Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1/2 9Phase NA 7Phase 1 7Phase 4 4Phase 3 3Phase EARLY_PHASE1 2Phase 2/3 1

Status

Completed 17Terminated 3Recruiting 3Active not recruiting 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 92Breast Neoplasms 85Neoplasms 79Prostatic Neoplasms 50Lung Neoplasms 43Neoplasm Metastasis 40Colorectal Neoplasms 37Leukemia, Myeloid, Acute 32Pain 27Head and Neck Neoplasms 25Colonic Neoplasms 25Multiple Myeloma 24Ovarian Neoplasms 23Lymphoma 23Carcinoma, Hepatocellular 23Pancreatic Neoplasms 22Lymphoma, Follicular 21Melanoma 20Leukemia 20Rectal Neoplasms 19Lymphoma, Non-Hodgkin 19Urinary Bladder Neoplasms 17Recurrence 17Stomach Neoplasms 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Squamous Cell Carcinoma of Head and Neck 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leiomyoma 13Brain Neoplasms 13

Interventions

trametinib 1tilsotolimod 1spartalizumab 1dabrafenib 1bempegaldesleukin 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Skin Neoplasms × Clear all
NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated
568 enrolled 28 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated
765 enrolled 13 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡